Navigation Links
Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Date:9/3/2008

This analysis showed that Multaq(R) (dronedarone) decreased the risk of stroke by 34% in patient with atrial fibrillation or atrial flutter already

adequately treated by antithrombotic therapy

BRIDGEWATER, N.J., Sept. 3 /PRNewswire-FirstCall/ -- The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany. Previous results from the landmark ATHENA study have shown that the investigational medicine Multaq(R) (dronedarone) on top of standard therapy decreased the combined primary endpoint of the risk of cardiovascular hospitalizations or death from any cause by a statistically significant 24% (p=0.00000002) as compared to placebo.

The ATHENA stroke post-hoc analysis on non-pre-specified secondary endpoints showed that Multaq(R) decreased the risk of stroke (ischemic or haemorrhagic) compared to placebo by 34% (46 vs 70 stroke events respectively; p=0.027) in atrial fibrillation / atrial flutter patients adequately treated by standard therapy including antithrombotics.

The significant reduction in stroke risk with Multaq(R) was incremental to background anti-thrombotic therapy like oral anticoagulants and / or anti-platelet agents. Similar to the ATHENA primary endpoint of CV hospitalizations or death, this effect appeared early and was maintained during the study follow-up (12 to 30 months).

"ATHENA is a landmark trial that will lead to a paradigm shift in the management of atrial fibrillation as it is the first time that an anti-arrhythmic drug has shown a significant impact on cardiovascular outcomes. As stroke is one of the leading complications of atrial fibrillation, and a major cause of death and long-term disability, these new results demonstrate the unique profile of Multaq(R) beyond its pure rhythm and rate-controlling effects," said Professor Stuart Connolly, Mc Master Uni
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
2. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
3. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
4. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
5. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
6. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
7. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
8. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
9. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
10. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
11. Arpida Provides Further Comments on the Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Tobramycin Market, 2010-2019" ... traditional antibiotic whose eye drop and ointment are the ... infection or inflammation caused by eye infection. Currently, dozens ... able to produce tobramycin, among which the Top 5 ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Developed by ... selective prostaglandin receptor agonist which effectively reduces intraocular ... by FDA, latanoprost (under the trade name of ...
(Date:8/28/2015)... 2015  Perrigo Company plc ("Perrigo") (NYSE: PRGO ... acquisition of leading OTC brands from GSK in an ... is a clear demonstration of Perrigo,s unique ability to ... network spanning 36 countries.  Perrigo Chairman, ... "We are excited to complete this transaction, which clearly ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... PharMEDium Healthcare Corporation has become an Industry Supporter of ... of a new Corporate Supporter program available to pharmaceutical, ... N. Jonas, PharMEDium Chairman and CEO commented, "We are ... field through leadership, education and research.  As a leading ...
... FAIRFAX, Va., April 11, 2011 General Dynamics ... (NYSE: GD ), has been awarded ... training instrumentation suite into the Vincennes University hospital ... a realistic training environment for the continuing education ...
Cached Medicine Technology:PharMEDium Becomes a Corporate Supporter of the American Society of Anesthesiologists (ASA) 2General Dynamics' InForce™ Training Toolkit to Support Vincennes University Hospital Simulation Lab 2
(Date:8/30/2015)... ... August 30, 2015 , ... InHealth Media ... the new Global Communications Director for InHealth Media. Mr. Spector comes with ... last 16 years doing on-air television, producing shows, on air-radio and media relations. ...
(Date:8/30/2015)... ... August 30, 2015 , ... Certified Nutrition Businessman Reid Eckert agrees to ... InHealth media is a global sales and communications firm that offers U.S. brands a ... our business relationship with Mr. Reid Eckert, as his interpretation of the nutritional needs ...
(Date:8/30/2015)... , ... August 30, 2015 , ... ... has been promoted from Administrative assistant to Executive Assistant to CEO Mitch Gould ... a proven professional, focused on your goals. Kathleen graduated from Florida State ...
(Date:8/29/2015)... , ... August 30, 2015 , ... Rio Salado ... to serve as the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, ... to help the college expand its reach and impact through innovative technologies and strategies. ...
(Date:8/29/2015)... ... August 30, 2015 , ... ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The ... simple digital handwritten signature. , Clinical trial sites can now use ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4
... Calif. (October 20, 2012) African American women who develop ... risk of developing diabetes in the future compared to white ... Permanente study published online in the journal Diabetologia . ... develop GDM during pregnancy. But for those who were diagnosed ...
... By Randy Dotinga HealthDay Reporter , WEDNESDAY, Oct. ... the best time to begin AIDS drug treatments in HIV-positive ... common in Africa. Starting the drugs earlier, even by a ... are very sick, the research suggests. The cost ...
... News) -- ,Some of the genetic traits that give ... researchers. The findings will help efforts to understand ... provide molecular markers for surveillance. "Different bedbug populations ... in their levels of resistance and resistance strategies, so ...
... (HealthDay News) -- An antiseizure drug called primidone (Mysoline) ... are the most effective medicines to treat shaking in ... guideline from the American Academy of Neurology. Essential ... United States, is the most common type of tremor ...
... VA The Patient Protection and Affordable Care Act ... agenda for pragmatic and clinical trials that provide optimal ... October 2011 issue of Otolaryngology Head and Neck ... Drug Development recently reported that the median number of ...
... HealthDay Reporter , WEDNESDAY, Oct. 19 (HealthDay News) ... guidelines for cervical cancer testing for women, including when ... intervals between screenings and in some cases, supplementing the ... The American Cancer Society, the American Society for ...
Cached Medicine News:Health News:African-American women with gestational diabetes face high long-term diabetes risk 2Health News:Start HIV Drug Treatment Early in Patients With TB: Studies 2Health News:Start HIV Drug Treatment Early in Patients With TB: Studies 3Health News:New Guidelines Issued for Common Tremor Disorder 2Health News:Evidence-based medicine in health-care reform 2Health News:U.S. Cancer Groups Release Their Own Cervical Cancer Screening Guidelines 2Health News:U.S. Cancer Groups Release Their Own Cervical Cancer Screening Guidelines 3
Knowles Pins are available in 9" (228mm) overall length with 9/64" (3.5mm) shaft diameter and 1/4" (6.4mm) square bead....
... Calibrated Guide Wires are available in two ... 9 in. length. Material: DePuy certified stainless ... ,Smooth wires etched in 1/2 in. ... also available. Etched in 1/2 in. ...
Kirschner Wires are available in four point styles ranging from .028 to .062 in. Smooth tip wire available in 4, 6 and 9 in. lengths. Threaded tip available. Material: DePuy certified stainless steel...
... Non-Donor Supplemental: Calypte Biomedical ... HIV-1 antibody testing algorithm as well ... Western Blot Kit [Human Immunodeficiency Virus ... products represent a portfolio of established ...
Medicine Products: